JAGUAR HEALTH, INC. Additional Paid in Capital, Common Stock
JAGUAR HEALTH, INC. (JAGX) had Additional Paid in Capital, Common Stock of $411.61 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-19
- 2026-06-30: Additional Paid in Capital, Common Stock $411.61M.
- 2026-03-31: Additional Paid in Capital, Common Stock $378.13M.
- 2025-12-31: Additional Paid in Capital, Common Stock $380.97M.
- 2025-09-30: Additional Paid in Capital, Common Stock $380.84M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $411.61M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $378.13M 10-Q · filed 2026-05-20 | |
| 2025-12-31 | $380.97M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $380.84M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $373.57M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $359.43M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $354.23M 10-K · filed 2026-04-07 | |
| 2024-09-30 | $350.86M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $344.15M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $329.65M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $313.86M 10-K · filed 2025-03-31 | $313.85M 10-K · filed 2024-04-01 |
| 2023-09-30 | $301.23M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $297.66M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $287.38M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $266.97M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $263.00M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $249.55M 10-Q · filed 2022-08-22 | |
| 2022-03-31 | $245.52M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $231.10M 10-K · filed 2023-03-24 | $231.10M 10-K · filed 2022-03-11 |
| 2021-09-30 | $226.73M 10-Q · filed 2021-11-17 | |
| 2021-06-30 | $224.76M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $210.79M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $184.10M 10-K · filed 2022-03-11 | $184.09M 10-K · filed 2021-03-31 |
| 2020-09-30 | $160.24M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $150.88M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $145.86M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $142.05M 10-K · filed 2021-03-31 | $142.05M 10-K · filed 2020-04-03 |
| 2019-09-30 | $138.10M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $117.93M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $109.64M 10-Q · filed 2019-05-21 | |
| 2018-12-31 | $99.93M 10-K · filed 2020-04-03 | $99.93M 10-K · filed 2019-04-10 |
| 2018-09-30 | $92.22M 10-Q · filed 2018-11-19 | |
| 2018-06-30 | $89.77M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $89.09M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $79.66M 10-K · filed 2019-04-10 | $79.66M 10-K · filed 2018-04-09 |
| 2017-09-30 | $74.00M 10-Q · filed 2017-11-20 | |
| 2017-06-30 | $40.69M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $38.96M 10-Q/A · filed 2017-06-23 | |
| 2016-12-31 | $37.98M 10-K · filed 2018-04-09 | |
| 2016-09-30 | $36.49M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $34.91M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $34.33M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $30.10M 10-K · filed 2017-02-15 | |
| 2015-09-30 | $29.94M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $29.72M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $1.49M 10-Q · filed 2015-06-26 | |
| 2014-12-31 | $1.18M 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |